S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Integra LifeSciences Stock Forecast, Price & News

+0.59 (+1.09%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.47 million shs
Average Volume
410,449 shs
Market Capitalization
$4.53 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Stock Forecast (MarketRank)

Overall MarketRank

2.19 out of 5 stars

Medical Sector

377th out of 1,417 stocks

Surgical & Medical Instruments Industry

47th out of 138 stocks

Analyst Opinion: 3.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Integra LifeSciences logo

About Integra LifeSciences (NASDAQ:IART)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$169.07 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.54 billion
Cash Flow
$4.76 per share
Book Value
$19.89 per share


Free Float
Market Cap
$4.53 billion

Social Links

Integra LifeSciences Frequently Asked Questions

Should I buy or sell Integra LifeSciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences
or view top-rated stocks.

What is Integra LifeSciences' stock price forecast for 2022?

7 brokerages have issued 12-month price targets for Integra LifeSciences' shares. Their IART stock forecasts range from $65.00 to $87.00. On average, they predict Integra LifeSciences' share price to reach $71.83 in the next year. This suggests a possible upside of 31.8% from the stock's current price.
View analysts' price targets for Integra LifeSciences
or view top-rated stocks among Wall Street analysts.

How has Integra LifeSciences' stock price performed in 2022?

Integra LifeSciences' stock was trading at $66.99 at the beginning of 2022. Since then, IART stock has decreased by 18.7% and is now trading at $54.49.
View the best growth stocks for 2022 here

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Integra LifeSciences

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) announced its quarterly earnings data on Wednesday, April, 27th. The life sciences company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.06. The life sciences company had revenue of $376.60 million for the quarter, compared to analysts' expectations of $362.19 million. Integra LifeSciences had a trailing twelve-month return on equity of 16.88% and a net margin of 10.04%. Integra LifeSciences's revenue was up 4.6% compared to the same quarter last year. During the same period last year, the business posted $0.69 EPS.
View Integra LifeSciences' earnings history

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Integra LifeSciences's stock split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share (EPS) guidance of $3.27-3.35 for the period, compared to the consensus EPS estimate of $3.31. The company issued revenue guidance of $1.58-1.60 billion, compared to the consensus revenue estimate of $1.59 billion.

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences CEO Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among Integra LifeSciences' employees.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (8.20%), Vanguard Group Inc. (7.88%), Champlain Investment Partners LLC (6.72%), Eaton Vance Management (5.07%), Clearbridge Investments LLC (3.07%) and Cooke & Bieler LP (3.04%). Company insiders that own Integra LifeSciences stock include Daniel L Reuvers, Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Kenneth Burhop, Lisa Evoli, Michael J Mcbreen, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends for Integra LifeSciences

Which institutional investors are selling Integra LifeSciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Champlain Investment Partners LLC, Vanguard Group Inc., Great Lakes Advisors LLC, Tributary Capital Management LLC, UBS Group AG, State of Tennessee Treasury Department, and First National Bank of Omaha. Company insiders that have sold Integra LifeSciences company stock in the last two years include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Stuart Essig, and Tru St Partnership, LP.
View insider buying and selling activity for Integra LifeSciences
or view top insider-selling stocks.

Which institutional investors are buying Integra LifeSciences stock?

IART stock was purchased by a variety of institutional investors in the last quarter, including Leeward Investments LLC MA, Arrowstreet Capital Limited Partnership, Cooke & Bieler LP, Renaissance Technologies LLC, Qube Research & Technologies Ltd, Eaton Vance Management, Fuller & Thaler Asset Management Inc., and First Trust Advisors LP.
View insider buying and selling activity for Integra LifeSciences
or or view top insider-buying stocks.

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $54.49.

How much money does Integra LifeSciences make?

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $4.53 billion and generates $1.54 billion in revenue each year. The life sciences company earns $169.07 million in net income (profit) each year or $1.839990 on an earnings per share basis.

How many employees does Integra LifeSciences have?

Integra LifeSciences employs 3,800 workers across the globe.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for Integra LifeSciences is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at [email protected], or via fax at 609-750-4277.

This page (NASDAQ:IART) was last updated on 6/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.